Accueil > Actualité > Société

J&J: encouraging results in multiple myeloma

( - The Janssen pharmaceutical companies of Johnson & Johnson today announced top-line results from a phase 1b study of Tecvayli (teclistamab-cqyv) and talquetamab, showing a high overall response rate in patients with relapsed or refractory multiple myeloma (RRMM).

These results highlight the potential combinability of these two novel bispecific therapies, which target distinct antigens on myeloma cells.

The investigational combination immunotherapy regimen demonstrated an overall response rate of 86.6% (71/82) at all dose levels, and an overall response rate of 96.3% (26/27) in patients receiving the recommended Phase 2 regimen.

These data were presented in an oral session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting.

Copyright (c) 2023 All rights reserved.





A quel niveau sera le CAC40 à fin décembre 2023:

En hausse à 7650Pts
En hausse à 7480Pts
Stable sur le niveau des 7230Pts
En baisse à 7100Pts
En baisse à 6850Pts
Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.